Protecting and enforcing intellectual property

Intellectual property is arguably the most important asset of any life sciences company, which means that ensuring its prompt and comprehensive protection is essential. This section explains these issues and provides guidance on how to enforce your IP in the case of a suspected infringement.

Protecting and Enforcing Intellectual Property
Countdown to the UPC: the Taylor Wessing webinar series
European trade mark reform: all change from 23 March 2016
Attention returns to decisions on UPC opt-out
Unified Patent Court fees
Methods of treatment and dosage regimes
Scope of protection of claims and Markush formulae
The role of experts in life sciences patent litigation
Unitary patent fees proposals
Largest damages award on cross-undertaking upheld on appeal
Opening the door to open innovation
Strategic considerations - why opt-out or why not?
Obligations under the Specific Mechanism (update) - decision of the CJEU
Hearing, seeing, moving Part 2 - key issues in regulation and protection
Infringer surcharge and punitive damages under European law?
CTMs for 'Chemicals for pharmaceutical use'
Languages in the Unitary Patent
Not all Bolar exemptions are the same
Patentability of parthenogenic stem cells
Pharmaceutical trade mark confusion
Infringement of second medical use claims in Germany
Obtaining evidence of infringement: preservation and seizure
Compensating employee inventors
Who is entitled to a patent?
What the new customs regulation means in practice
Plant Breeders’ Rights
An introduction to patents and patent infringement
joint patents and regulatory strategy
what legislation governs patent law
Registration of assignments and licences of patent rights
The importance of IP due diligence
Confidentiality and related protection
Supplementary protection certificates
Another round of SPC references
EMA adopts policy on publication of clinical trial data